ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Biomimetic Nanoplatform for Targeted Rheumatoid Arthritis Therapy: Modulating Macrophage Niches Through Self-Sustaining Positive Feedback-Driven Drug Release Mechanisms.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Microglia-Targeted Biomimetic Tetrahedral Framework Nucleic Acid Nanovesicles for Synergistic Treatment of Sepsis-Associated Encephalopathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Potential new targets for rheumatic diseases.EULAR rheumatology open · 2026Review
- Advances in nanotechnology for the diagnosis and management of autoimmune diseases.Asian journal of pharmaceutical sciences · 2026Review
- Nanotherapeutic Macrophage-Neuro Reprogramming Through Immunometabolic Crosstalk Mitigates Sepsis-Induced Lung Injury and Neurologic Damage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Microneedle patches deliver targeted GLP-1RAs-loaded nanoparticles for the treatment of rheumatoid arthritis.Journal of nanobiotechnology · 2026Article
- Programmable ROS modulation by nanomedicine for rheumatoid arthritis treatment.Materials today. Bio · 2026Review
- Smart Polymer Nanoparticles: Targeting Macrophages/Fibroblasts and Modulating the Microenvironment for Rheumatoid Arthritis Therapy.International journal of nanomedicine · 2026Review
- Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy.International journal of nanomedicine · 2026Review
- Therapeutic Nanozymes in Rheumatoid Arthritis Treatment Through Disease Stage-Oriented Strategies.International journal of nanomedicine · 2026Review
- Nanotechnology-driven strategies for gene therapy of arthritis.Materials today. Bio · 2025Review
- Biomimetic Nanoplatform for Targeted Rheumatoid Arthritis Therapy: Modulating Macrophage Niches Through Self-Sustaining Positive Feedback-Driven Drug Release Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent Advances in Biomimetic Drug Delivery for Rheumatoid Arthritis Treatment.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The core strategies in treating rheumatoid arthritis (RA) now focus on ameliorating the inflammatory microenvironment and reversing macrophage phenotypes within the joint cavity. This study introduces a co-delivery system of integrating nanoenzymes and gene therapeutics sequentially modified with guanidinium-based polymers and macrophage membranes to achieve synergistic therapeutic effects. This co-delivery system is named MACP siTNF-α nanoparticles (NPs). MACP siTNF-α nanoparticles are designed for targeted delivery to the inflamed joint site, where they are preferentially internalized by M1-type macrophages and efficiently evade lysosomal degradation. Subsequently, the co-delivery system operates efficiently via a self-sustaining positive feedback drug release mechanism. The biomimetic nanoplatform reduces reactive oxygen species (ROS) levels and prevents glutathione (GSH) depletion. GSH degrades the polymers to release small interfering RNA (siRNA) and expose the Prussian blue (PB) nanoenzymes, which effectively scavenge ROS and restore GSH levels. This feedback loop significantly enhances the gene silencing capability and ROS scavenging efficiency of the co-delivery system. In summary, MACP siTNF-α NPs can reverse macrophage ecological niche in inflammatory soils through the dual mechanism of efficiently inhibiting the expression of tumor necrosis factor-alpha (TNF-α) the upstream pathway of the inflammatory response, and eliminating ROS, thus realizing efficient treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.